SCHEMBL3103489

SCHEMBL3103489

CCN(C(=O)C(CC#N)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.48
CTSS P25774 1/20 0.46
NLRP3 Q96P20 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
RAPGEF3 O95398 1/20 0.40
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 1/20 0.39
KAT6A Q92794 5/20 0.38
F2 P00734 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092105 0.90 LARS1 (0.47) LARS1CTSSNLRP3MEN1KMT2A
SCHEMBL3085527 0.90 LARS1 (0.48) LARS1CTSSNLRP3MEN1KMT2A
SCHEMBL3093550 0.85 LARS1 (0.44) LARS1CTSSNLRP3KAT6AF2
SCHEMBL3103936 0.85 LARS1 (0.49) LARS1CTSSNLRP3MEN1KMT2A
SCHEMBL3085146 0.83 LARS1 (0.46) LARS1CTSSNLRP3MEN1KMT2A
SCHEMBL3085143 0.83 LARS1 (0.46) LARS1CTSSNLRP3MEN1KMT2A
SCHEMBL3100295 0.83 LARS1 (0.47) LARS1NLRP3MEN1KMT2ARAPGEF3
SCHEMBL3086151 0.82 SLC16A3 (0.47) LARS1F2
SCHEMBL3083515 0.82 LARS1 (0.46) LARS1MEN1KMT2ALMNAKAT6A
SCHEMBL3093111 0.82 LARS1 (0.46) LARS1NLRP3MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885CTSS 1116/4885NLRP3 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.